# Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct05601505/  
OnCo record `nct05601505` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Peking Union Medical College Hospital, now recruiting.

## Summary

Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT05601505 by Peking Union Medical College Hospital, with a registry enrolment figure of 470 participants, started 2023-02-03 and due to reach its primary completion in 2025-10-31. Interventions recorded: circulating tumor DNA. Conditions listed: Locally Advanced Rectal Carcinoma; Circulating Tumor DNA. Primary outcome: two-year disease-related treatment failure, 2y-DrTF. Colorectal eligibility wording from the registry: "Rectal adenocarcinoma confirmed by pathology;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CINTS-R
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05601505
- Phase: 2
- Setting: Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer --- a Multicenter Randomized Controlled Trial (CINTS-R)
- Sponsor: Peking Union Medical College Hospital
- Enrolled: 470

## Sources

- ClinicalTrials.gov NCT05601505: https://clinicaltrials.gov/study/NCT05601505

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05601505.json